BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25849939)

  • 1. Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo.
    Sai S; Wakai T; Vares G; Yamada S; Kamijo T; Kamada T; Shirai T
    Oncotarget; 2015 Mar; 6(8):5517-35. PubMed ID: 25849939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro.
    Sai S; Vares G; Kim EH; Karasawa K; Wang B; Nenoi M; Horimoto Y; Hayashi M
    Mol Cancer; 2015 Sep; 14():166. PubMed ID: 26338199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells.
    Oonishi K; Cui X; Hirakawa H; Fujimori A; Kamijo T; Yamada S; Yokosuka O; Kamada T
    Radiother Oncol; 2012 Nov; 105(2):258-65. PubMed ID: 23017870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays.
    Cui X; Oonishi K; Tsujii H; Yasuda T; Matsumoto Y; Furusawa Y; Akashi M; Kamada T; Okayasu R
    Cancer Res; 2011 May; 71(10):3676-87. PubMed ID: 21454414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
    Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
    Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines.
    El Shafie RA; Habermehl D; Rieken S; Mairani A; Orschiedt L; Brons S; Haberer T; Weber KJ; Debus J; Combs SE
    J Radiat Res; 2013 Jul; 54 Suppl 1(Suppl 1):i113-9. PubMed ID: 23824114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbon-Ion Beam Irradiation and the miR-200c Mimic Effectively Eradicate Pancreatic Cancer Stem Cells Under in vitro and in vivo Conditions.
    Sai S; Kim EH; Koom WS; Vares G; Suzuki M; Yamada S; Hayashi M
    Onco Targets Ther; 2021; 14():4749-4760. PubMed ID: 34556996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
    Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
    Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of carbon-ion beam and dual tyrosine kinase inhibitor, lapatinib, effectively destroys HER2 positive breast cancer stem-like cells.
    Sai S; Kim EH; Vares G; Suzuki M; Yu D; Horimoto Y; Hayashi M
    Am J Cancer Res; 2020; 10(8):2371-2386. PubMed ID: 32905515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
    Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
    Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.
    Du Z; Qin R; Wei C; Wang M; Shi C; Tian R; Peng C
    Dig Dis Sci; 2011 Mar; 56(3):741-50. PubMed ID: 20683663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
    Isayev O; Rausch V; Bauer N; Liu L; Fan P; Zhang Y; Gladkich J; Nwaeburu CC; Mattern J; Mollenhauer M; Rückert F; Zach S; Haberkorn U; Gross W; Schönsiegel F; Bazhin AV; Herr I
    Oncotarget; 2014 Jul; 5(13):5177-89. PubMed ID: 25015789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
    Venkatesha VA; Parsels LA; Parsels JD; Zhao L; Zabludoff SD; Simeone DM; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2012 Jun; 14(6):519-25. PubMed ID: 22787433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
    Hong SP; Wen J; Bang S; Park S; Song SY
    Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.